
MyoGene Bio is developing cutting edge therapeutics for muscle diseases, starting with a gene editing therapy for Duchenne muscular dystrophy.
Market:
Duchenne muscular dystrophy (DMD) is a severe, progressive muscle wasting disorder that affects approximately 1 in 3,500-5,000 male births worldwide. It leads to premature death in the 20-30s. There is currently no cure and only limited treatments for DMD. MyoGene Bio's therapy, SPY-DYS45-55, would be applicable to approximately 50% of patients, meaning about 25,000 patients in the US and Europe or 190,000 patients worldwide. The overall dystrophin therapy market is estimated to reach $11B by 2026.Technology:
MyoGene Bio's therapy, SPY-DYS45-55, is a gene editing approach designed to permanently remove a mutational hotspot in the gene that causes Duchenne and allow for dystrophin, the protein otherwise lacking, to be expressed. This directly rescues the underlying cause of disease. By targeting a large region of the gene, MyoGene Bio's single therapy is applicable to a large cohort of Duchenne patients and is expected to create a very functional protein that would improve disease progression to a milder form.Advantages:
- Permanent gene editing
- Targets 50% of patients
- Transforms to mild disease progression
- Strategies to overcome immune response
Development Stage:
- Pre-clinical
Patents Issued:
- Methods and compositions for modifying a mutant dystrophin gene in a cell’s genome; WO2017139505A3
Select Publications:
- With a deft snip, potential treatment emerges for deadly childhood Duchenne Muscular Dystrophy | LA Times
- Stem cell gene therapy could be key to treating Duchenne muscular dystrophy | UCLA Newsroom
- A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells | Cell Stem Cell
- Creation of a novel humanized dystrophic mouse model of Duchenne muscular dystrophy and application of a CRISPR/Cas9 gene editing therapy | Journal of Neuromuscular Diseases
Contact:
Email: info@myogenebio.comWebsite: www.myogenebio.com
Graduated in 2022
Graduated Companies
- Adaptix
- Aneeve
- Aneuvo
- Appia Bio
- Bluefin Foods
- CarbonBuilt
- Carbonics
- Charlot Biosciences
- CBD Research Institute
- Cellmic
- Concrete-AI
- Craytex
- CytoLumina
- DARTS Sciences
- Electronucleics
- EP Dynamics
- Ferrologix
- Horizon PV
- Inspira
- Inston
- InvVax
- Kelvi
- Keyssa
- Kythera Biopharmaceuticals
- Librede
- Lucendi
- Matrix Sensors, Inc.
- MAX BioPharma
- MediSens Wireless
- MicrobeDx
- Millibatt
- MyoGene Bio
- Myst Therapeutics
- Nammi Therapeutics
- NanoClear
- NanoElectronic Imaging
- NanoH₂O
- Nanopixel Technologies
- National Institute of Cannabinoid Research (NICR)
- Octant
- Omega Biosystems
- Orchard Therapeutics
- Polyradiant
- Qwixel Therapeutics
- Restore Technologies
- Sardona Therapeutics
- SELFA
- Sixal
- Spectradyne Particle Analysis
- Tempo Therapeutics
- TrueCath
- U-Defi
- Valerion Therapeutics
- Vivibaba
- Zenomics
- Back to Portfolio